Webinar:

Head and Neck Cancer

Sponsored by: GlobalData

Focused on:

  • Head Cancer
  • Neck Cancer
  • Squamous Cell Carcinoma

Date: 24 April

Days to go: 3

Time: 3PM London/10AM New York

Current and Future Trends

This expert presentation is exclusive only for GlobalData's clients. The webinar recording and presentation will be available on the Intelligence Center. For any requests or questions about this webinar please contact kim.roz@globaldata.com

Head and neck cancer (HNC) is the ninth most diagnosed cancer. HNC is an umbrella term to describe a heterogeneous group of cancers, involving those that arise in the lips and oral cavity, pharynx, larynx, salivary glands, nasal cavity of the paranasal sinuses and the thyroid glands. The most common form of HNC is squamous cell carcinoma which generally arises in the mucosal epithelium.

Overall, patient survival for head and neck squamous cell carcinoma (HNSCC) is poor and patients that present with early-stage disease (Stage I-II) have a much better prognosis than those who present with locally-advanced HNSCC (Stage III-IVb).

Until recently, there has been little interest in the HNC market with few competitors and a stagnant pipeline. Historically, generic chemotherapies made up the majority of the head and neck squamous cell carcinoma (HNSCC) market, with only one targeted agent, Erbitux (cetuximab), approved in 2006 for the indication.

In 2016, PD-1 inhibitors, Opdivo (nivolumab) and Keytruda (pembrolizumab) gained approval for patients that had progressed after treatment with platinum-based chemotherapies in the recurrent/metastatic (r/m) HNSCC setting. This emergence of immunotherapies has created a huge spark of interest in the HNC space. Many companies have started to develop their own immunotherapies and are expected to launch novel label-expansions and combinations during 2016-2026 for patients with HNSCC.

In this expert presentation Ashwin Oberoi, Healthcare Analyst at GlobalData, will present the drug forecast and market analysis to 2026, drawing on key insights from GlobalData's recently published report, Head and neck cancer: Opportunity Analysis and Forecasts to 2026. The current treatment options and drug pipeline for head and neck cancer will be covered, including a discussion on GlobalData's sales forecasts for the most impactful HNC therapies.

The expert presentation will cover insights from various key opinion leaders (KOLs) on the current treatment options, pipeline drugs, the unmet needs, and the most promising R&D strategies. Dr. Heather Leach, Associate Director of Oncology and Hematology at GlobalData will moderate the Q&A session following the presentation.

Presented by

Ashwin Oberoi,

Oncology Analyst, GlobalData

Ashwin Oberoi MChem is an Oncology Analyst based in London, working within the GlobalData Healthcare Pharmaceuticals team.

He provides in-depth scientific analysis of products within the oncology pharmaceutical sector, and constructs market forecast models based on business intelligence. Ashwin received his Masters in Chemistry from the University of Oxford specializing in nanotechnology, with a supplementary specialty in Chemical Pharmacology.

Prior to joining GlobalData, Ashwin worked as an external consultant for an Irish-based medical devices company and an analyst for a US-based biotechnology hedge-fund.

Heather Leach,

Oncology and Hematology Therapy Director, GlobalData

Heather Leach, PhD, is the Associate Director (AD) of Oncology and Hematology at GlobalData in New York City. Heather has 10 years of basic research experience in molecular biology and immunology and several years’ experience as an analyst and consultant for the biopharmaceutical industry.

Prior to joining GlobalData as an AD, she worked as an analyst in immunology and neurology and as a consultant for a boutique life sciences consulting firm in New York City. She has worked in various academic and pharmaceutical research labs at the University of Connecticut, Boston University School of Medicine, and Pfizer, covering human diseases such as sepsis, systemic sclerosis, and idiopathic pulmonary fibrosis. Heather holds a Bachelor's degree in Molecular and Cell Biology from the University of Connecticut, and a PhD in Pathology and Cell and Molecular Biology from Boston University School of Medicine.

Key Learning Objectives

  • Learn how the head and neck cancer market dynamics are expected to change between 2016 and 2026 across the 7 major markets (US, France, Germany, Italy, Spain, UK and Japan)
  • Gain in-depth insight about the late-stage head and neck cancer pipeline, including the products that are expected to dominate the market and the key drivers behind these.
  • Understand the unmet needs that key opinion leaders (KOLs) have identified in the head and neck treatment space and an analysis on whether the current pipeline will meet these needs.
  • Learn about some of the key R&D strategies, growth drivers, and barriers in the head and neck cancer market across the 7MM.

Audience

  • Managers/Senior Managers/Associate Directors/Directors of Market Research
  • Business Insights
  • Market Intelligence
  • Strategic Insights
  • Forecasting
  • Pipeline Management
  • Competitive Strategy
  • Customer Insights
  • Heads of Research and Development
  • Heads of Product Planning and Marketing
  • Brand Managers